Roa J C, Villaseca M A, Roa I, Araya J C, Okayasu I, Flores P, Flores M
Unidad de Anatomía Patológica, Facultad de Medicina, Universidad de la Frontera, Temuco, Chile.
Rev Med Chil. 1997 May;125(5):523-9.
Colorectal carcinoma is the sixth cause of death in Chile. Half of malignant tumors in humans have genetic alterations in protoncogenes, tumor suppressing genes or both. One of the most frequent alterations is that involving p53 tumor suppressor gene.
To study, using immunohistochemical methods, alterations in p53 gene expression in colorectal carcinomas and adenomas.
A random sample of 28 large bowel adenomas and 44 carcinomas was studied. Determination of p53 protein was made with an immunohistochemical method using monoclonal antibodies. Patients were followed for a mean of 36 months (range 1 to 100 months).
p53 immunostaining was obtained in one adenoma (3.5%) and in 18 carcinomas (41%, p = 0.01). There were no differences in survival during follow up, between cancer patients that expressed or did not express p53 protein.
About half of colorectal tumors have immunohistochemical expression of p53 protein, as published abroad. We did not find a prognostic value for this protein in our sample.
在智利，结直肠癌是第六大致死原因。人类一半的恶性肿瘤在原癌基因、抑癌基因或两者中存在基因改变。最常见的改变之一是涉及p53抑癌基因的改变。
采用免疫组化方法研究结直肠癌和腺瘤中p53基因表达的改变。
对28例大肠腺瘤和44例癌的随机样本进行研究。使用单克隆抗体通过免疫组化方法测定p53蛋白。对患者进行了平均36个月（范围1至100个月）的随访。
在1例腺瘤（3.5%）和18例癌（41%，p = 0.01）中获得了p53免疫染色。在随访期间，表达或未表达p53蛋白的癌症患者的生存率没有差异。
约一半的结直肠肿瘤有p53蛋白的免疫组化表达，正如国外所报道的那样。在我们的样本中，未发现该蛋白有预后价值。
